Metastatic non-seminomatous testicular tumour patients with residual retroperitoneal tumour masses >1 cm after chemotherapy are treated with pcRPLND to remove viable tumours and teratoma, which are present in approximately 10% and 40% of cases, respectively. However, histopathology only identifies scar tissue/necrosis in up to 50%. In those patients, surgical therapy is not necessary, resulting in a relevant overtreatment. So far, no adequate pre-operative distinction between the histologies exists. Recently, the first biomarker was described with miR371a-3p in serum, which is highly specific for viable testicular germ cell tumours (GCT) but not for teratoma and/or necrosis [1].
Dr Tim Nestler (University of Cologne, Germany) presented results from a study aimed to identify mRNAs and proteins that are differentially expressed between viable tumours, teratoma, and necrosis in pcRPLND-resected cells [2]. Included were 48 patients, 16 in each histology subgroup. Representative regions were micro-dissected and subjected to mRNA analysis and a comprehensive proteomics analysis.
For the comparison of teratoma and necrosis, 84 mRNAs and 25 proteins were significantly differentially expressed. Only 2 proteins, anterior gradient 2 (AGR2) and cytokeratin 19 (KRT19), had significantly differential expressions on both levels.
“With AGR2 and KRT19, we have identified 2 proteins with their corresponding genes that are significantly and differentially expressed in the pcRPLND specimen in the clinically relevant groups teratoma and necrosis,” concluded Dr Nestler. “In perspective, these proteins could be targeted by radiolabelled ligands as a tracer in order to reliably distinguish patients with teratoma from those with necrosis by means of functional imaging. Thus, overtreatment with pcRPLND of patients with necrosis could be safely reduced.”
- Diekman KP, et al. J Clin Oncol. 2019;37:1412–1423.
- Nestler T, et al. Differentially expressed mRNA/proteins can distinguish viable germ cell tumors and teratomas from necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND). Abstract 408, ASCO GU 2022, 17–19 February.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Lithium linked to lower risk of osteoporosis in bipolar disorder Next Article
Atezolizumab does not improve survival in advanced penile cancer »
« Lithium linked to lower risk of osteoporosis in bipolar disorder Next Article
Atezolizumab does not improve survival in advanced penile cancer »
Table of Contents: ASCO GU 2022
Featured articles
Prostate Cancer
First-line treatment with olaparib significantly improves PFS in mCRPC
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC
Darolutamide improves OS in mHSPC
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel
Artificial intelligence improves prediction of long-term outcomes
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity
Urothelial Carcinoma
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma
Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma
Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma
Maintenance niraparib fails to improve PFS in advanced urothelial cancer
First-line avelumab shows clinical activity in advanced urothelial carcinoma
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
Renal Cell Carcinoma
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC
Folliculin mutations not associated with sporadic chromophobe RCC
Differential patterns of molecular alterations among sites of metastasis in RCC
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC
Penile & Testicular Cancer
HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours
Atezolizumab does not improve survival in advanced penile cancer
Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer
Related Articles
May 21, 2019
When to use imaging and imaging-guided therapies
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com